トキソプラズマ溶解抗原によるマウスのPiroplasma感染死防御効果

DOI 日本農学文献記事索引 Web Site Web Site PubMed

書誌事項

タイトル別名
  • Preventive effect of Toxoplasma lysate antigen (TLA) on fatal infection with mouse piroplasma.
  • トキソプラズマ溶解抗原によるマウスのpiroplasma感染死防御効果〔英文〕
  • トキソプラズマ ヨウカイ コウゲン ニ ヨル マウス ノ piroplasma

この論文をさがす

抄録

Toxoplasma Lysate antigen (TLA), mouse Babesia lymphokines (B-LKs) and mouse Toxoplasma lymphokines (Tp-LKs), were used to examine the effect of immune adjuvant in reducing clinical symptoms of Babesia rodhaini infection in mice. Normal mice were treated twice at an interval of two weeks with an emulsion of TLA in Freund's incomplete adjuvant (TLA emulsion), or a combination of TLA emulsion and B-LKs or Tp-LKs. Two weeks after the second treatment, these mice were infected with B. rodhaini (102 parasitized erythrocytes/mouse, i.p.). Thirty five point seven percent (5/14, number of survivals/number examined) of mice treated with TLA emulsion, 53.3% (8/15) of mice treated with a combination of TLA emulsion and B-LKs, and 73.3% (11/15) of mice treated with a combination of TLA emulsion and Tp-LKs, survived for more than 20 days postinfection. None of the mice in the non-treated control group survived for more than 12 days postinfection. The defence mechanisms possibly involved in the group treated with TLA emulsion and combination of TLA emulsion and Tp-LKs, were examined with respect to macrophage activation. Mice treated with TLA emulsion showed a slight increase of leukocyte count, and O2 release of macrophages. The activity of macrophage migration inhibitory factor (MIF) of spleen cell culture supernatant and serum was not increased in this group. The mice treated with a combination of TLA emulsion and Tp-LKs showed increased MIF activity and greater macrophage phagocytosis. These results suggest that treatment with TLA emulsion and a combination of TLA emulsion and B-LKs or Tp-LKs induces a degree of immunity in the host against Babesia infection, and that macrophage activation is part of this defence mechanism.

収録刊行物

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ